CoChat

Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin

Open access
Forrest, Caroline M., Mackay, Gillian M., Stoy, Nicholas, Stone, Trevor W., Darlington, L. Gail · 2007 · British Journal of Clinical Pharmacology
Cited by 105

The DOI matches its Crossref record.

Abstract

What is already known about this subject • There is good evidence that oxidative stress, associated with the generation of free radicals, is a major contributor to joint damage in rheumatoid arthritis. • It is also well established that melatonin is one of the most powerful, endogenous free radical scavengers, and it is very safe for human use. • We have therefore examined whether melatonin might be a useful adjunctive compound with which to treat arthritis. What this study adds • Once‐nightly administration of melatonin increases concentrations of some inflammatory markers, but patients experience no significant improvement in symptoms and no changes of proinflammatory cytokine concentrations. • Melatonin is an effective antioxidant, but because it is either not sufficiently effective, or it has some proinflammatory activity, it is not likely to prove beneficial in patients. Aim: Since melatonin is antioxidant and has some anti‐inflammatory actions, we have tested it as adjunctive treatment in patients with rheumatoid arthritis, to determine whether it can improve patients' symptoms. Methods: A total of 75 patients were allocated randomly to receive melatonin 10 mg at night in addition to ongoing medication, or a placebo of identical appearance. Monthly blood samples were taken and disease severity assessed over 6 months, plasma being analysed for inflammatory indicators [C‐reactive protein, erythrocyte sedimentation rate (ESR), neopterin], proinflammatory cytokines [interleukin (IL)‐1β, IL‐6, tumour necrosis factor (TNF)‐α], lipid peroxidation products and the kynurenine pathway metabolites of tryptophan. Results: An increase of ESR (two‐way anova F(1,127) = 5.24, P = 0.024) and neopterin concentrations (F(1,136) = 4.64, P = 0.033) was observed in treated patients compared with controls, reflected also in a significant trend for both to decline in placebo‐treated patients (P = 0.022), but not the melatonin‐treated group. Peroxidation products showed a significant trend to decrease in placebo‐ but not melatonin‐treated patients. These results suggest a proinflammatory action, but there were no significant effects of melatonin treatment on clinical assessments of patient symptoms or the concentrations of three proinflammatory cytokines, IL‐1β, IL‐6 and TNF‐α. Melatonin significantly increased plasma kynurenine concentrations (F(1,124) = 4.24, P = 0.041), again suggesting proinflammatory activity. Conclusion: A daily dose of 10 mg melatonin shows a slowly developing antioxidant profile in patients with arthritis and increases the concentrations of some inflammatory indicators, but these effects are not associated with any change of proinflammatory cytokine concentrations or clinical symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2007.02911.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 105

Metadata

Authors
Forrest, C. M., Mackay, G. M., Stoy, N., Stone, T. W., & Darlington, L. G.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2007-08-15
Volume
64
Issue
4
Pages
517-526
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2144981750
Cited by
105
References
0
FWCI
1.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. https://app.cochat.ai/papers/10.1111/j.1365-2125.2007.02911.x
The paper
Forrest, C. M., Mackay, G. M., Stoy, N., Stone, T. W., & Darlington, L. G. (2007). Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2007.02911.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.